PURPOSE: To evaluate peri-operative multicatheter interstitial pulsed-dose-rate brachytherapy (PDR-BT) with an intra-operative catheter placement to boost the @entity5 excision site in @entity0 @entity1 treated conservatively. MATERIAL AND METHODS: Between May 2002 and October 2008, 96 consecutive T1-3N0-2M0 @entity0 @entity1 underwent breast-conserving therapy (BCT) including peri-operative PDR-BT boost, followed by whole breast external beam radiotherapy (WBRT). The BT dose of 15 Gy (1 Gy/pulse/h) was given on the following day after surgery. RESULTS: No increased @entity548 or delayed wound healing related to the implants were observed. The only side effects included one case of temporary peri-operative @entity0 and 3 cases of fat @entity39 , both early and late. In 11 @entity1 (11.4%), subsequent WBRT was omitted owing to the final pathology findings. These included eight @entity1 who underwent mastectomy due to multiple adverse prognostic pathological features, one case of @entity1137 in situ, and two cases with no @entity5 . With a median follow-up of 12 years (range: 7-14 years), among 85 @entity1 who completed BCT, there was one ipsilateral @entity0 and one locoregional nodal recurrence. Six @entity1 developed distant @entity3 and one was diagnosed with @entity5426 within irradiated breast. The actuarial 5- and 10-year disease free survival was 90% (95% CI: 84-96%) and 87% (95% CI: 80-94%), respectively, for the @entity1 with @entity0 , and 91% (95% CI: 84-97%) and 89% (95% CI: 82-96%), respectively, for @entity1 who completed BCT. Good cosmetic outcome by self-assessment was achieved in 58 out of 64 (91%) evaluable @entity1 . CONCLUSIONS: Peri-operative PDR-BT boost with intra-operative tube placement followed by EBRT is feasible and devoid of considerable @entity137 , and provides excellent long-term local control. However, this strategy necessitates careful @entity1 selection and histological confirmation of primary diagnosis.

Pulsed-dose-rate peri-operative brachytherapy as an interstitial boost in organ-sparing treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1137 :: ('MESH:D018275', 'Disease') :: ['lobular carcinoma'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'breast infection', 'breast tumor', 'invasive breast cancer'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignant tumor'] @entity5426 :: ('MESH:D006394', 'Disease') :: ['angiosarcoma'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
